Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sheppard

Showing results (211-220 of 229) with videos related to

Pageof 23
Sort By:
Bioorganic & Medicinal Chemistry Letters|April 25, 2006
Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative propertiesMegumi Kawai, Nwe Y BaMaung, Steve D Fidanze, et al.
Journal of Cancer Research and Clinical Oncology|August 20, 2022
FLOT and CROSS chemotherapy regimens alter the frequency of CD27<sup>+</sup> and CD69<sup>+</sup> T cells in oesophagogastric adenocarcinomas: implications for combination with immunotherapyMaria Davern, Noel E Donlon, Andrew S Sheppard, et al.
Journal of Medicinal Chemistry|April 24, 2020
Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second BromodomainGeorge S Sheppard, Le Wang, Steven D Fidanze, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2010
Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinasesSteve D Fidanze, Scott A Erickson, Gary T Wang, et al.
Journal of Medicinal Chemistry|January 23, 1998
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonistsM L Curtin, S K Davidsen, H R Heyman, et al.
Cancer Research|April 19, 2017
Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic StrategiesMai H Bui, Xiaoyu Lin, Daniel H Albert, et al.
Journal of Medicinal Chemistry|June 23, 2006
Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin bindingGeorge S Sheppard, Jieyi Wang, Megumi Kawai, et al.
Cell Death & Disease|January 16, 2015
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)J D Leverson, H Zhang, J Chen, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2018
Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitorsSteven D Fidanze, Dachun Liu, Robert A Mantei, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2017
Methylpyrrole inhibitors of BET bromodomainsLisa A Hasvold, George S Sheppard, Le Wang, et al.
Pageof 23

Showing results (211-220 of 229) with videos related to

Sort By:
Pageof 23
Bioorganic & Medicinal Chemistry Letters|April 25, 2006
Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative propertiesMegumi Kawai, Nwe Y BaMaung, Steve D Fidanze, et al.
Journal of Cancer Research and Clinical Oncology|August 20, 2022
FLOT and CROSS chemotherapy regimens alter the frequency of CD27<sup>+</sup> and CD69<sup>+</sup> T cells in oesophagogastric adenocarcinomas: implications for combination with immunotherapyMaria Davern, Noel E Donlon, Andrew S Sheppard, et al.
Journal of Medicinal Chemistry|April 24, 2020
Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second BromodomainGeorge S Sheppard, Le Wang, Steven D Fidanze, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2010
Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinasesSteve D Fidanze, Scott A Erickson, Gary T Wang, et al.
Journal of Medicinal Chemistry|January 23, 1998
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonistsM L Curtin, S K Davidsen, H R Heyman, et al.
Cancer Research|April 19, 2017
Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic StrategiesMai H Bui, Xiaoyu Lin, Daniel H Albert, et al.
Journal of Medicinal Chemistry|June 23, 2006
Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin bindingGeorge S Sheppard, Jieyi Wang, Megumi Kawai, et al.
Cell Death & Disease|January 16, 2015
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)J D Leverson, H Zhang, J Chen, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2018
Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitorsSteven D Fidanze, Dachun Liu, Robert A Mantei, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2017
Methylpyrrole inhibitors of BET bromodomainsLisa A Hasvold, George S Sheppard, Le Wang, et al.
Pageof 23